ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 42

Small  Fibre Neuropathy Biopsies (SFN)  in  Primary Fibromyalgia Revealed  Predominant Association with Metabolic Syndrome (in addition to other known treatable causes of SFN)  but No Clear Distinction Related to Biopsy Results

Euthalia Roussou1, Johnathan Chan2, Istvan Bodi3 and Aleksandar Radunivics2, 1Rheumatology, Dr, London, United Kingdom, 2Neurologist, London, United Kingdom, 3Department of Clinical Neuropathology, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fibromyalgia, metabolic syndrome and small fiber neuropathy

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2016

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: To assess patients with primary fibromyalgia (pFM) for small fibre neuropathy (SFN) and to correlate biopsy results between groups and with known causes of SFN

Methods: A total of 21 patients with pFM (M:F=19:2) had 3mm skin punch biopsies from 2 leg sites-proximal and distal (20cm below right iliac crest and 10cm above right lateral malleolus) following appropriate consent. PGP-5 has been used as a pan axonal marker. Clinical assessments obtained on pain, sleep disturbance, effect of the disease on well being past week and past month , FM pain and FM fatigue ( all on a VAS 0-10; 10=worse positive). Fabro fatigue scale (0-90), Rotterdam emotional scale (30-120) ability to perform activities ( 8-32; 8 best ability). Each patient from the pFM group was examined for conditions known to be associated with SFN [1]: namely: Thyroid disease (hypo and hyper), metabolic syndrome, insulin resistance, diabetes, Family history (Fx) of diabetes, impaired Glucose tolerance, sarcoid, coeliac disease, B12 deficiency, chemotherapy drugs, para-neoplastic syndrome, antiviral drugs, Human Immunodeficiency Virus (HIV), Neurotoxins, palindromic rheumatism, Fx of psoriasis, hepatitis, Systemic Lupus Erythematosus, Sjogren’s, amyloidosis, restless syndrome, Guillain Barre, demyelinating polyneuropathy, complex regional pain syndrome and alcoholism. Demographic, ethnic, clinical, laboratory and disease associated comparisons between SFN(+) and SFN(-) biopsy groups took place.

Results: Age (mean) of the group was of 44.48 years (y) sd (+10.9) range (20-73). Age of symptoms onset was of 32.7 y (+ 10.9)(range 12-50) while mean age of diagnosis was 40.5 y (+ 8.9)(range 21-55). Data on tender point evaluation showed that all 21 patients were fulfilling 2011 criteria for FM while 18 of 21 patients were fulfilling the 1999 criteria having >11 tender points. Biopsy results showed 14 patients of 21 (66.6%) of pFM patients to be positive for SFN while 7 patients (33.3%) were negative. Looking at SFN associations, a total of 19 of 21 patients with pFM( 90.4%) had an associated cause from those listed related to SFN. More specifically 7 patients had metabolic syndrome (including diabetes and Fx of diabetes), 5 patients had hypothyroidism, 4 had B12 deficiency and 3 patients had family history of psoriasis. No predominant distribution according to biopsy results was found. Similarly no difference between the demographic, ethnic, clinical or laboratory characteristics between SFN (+) and SFN( -) found.

Conclusion: Metabolic syndrome along with other known causes of SFN is related to pFM. Reference: [1]. Hovaguimian A, Gibbons C. Diagnosis and treatment of pain in small fibre neuropathy. Curr Pain Headache Rep. 2011;15(3)193-200.


Disclosure: E. Roussou, None; J. Chan, None; I. Bodi, None; A. Radunivics, None.

To cite this abstract in AMA style:

Roussou E, Chan J, Bodi I, Radunivics A. Small  Fibre Neuropathy Biopsies (SFN)  in  Primary Fibromyalgia Revealed  Predominant Association with Metabolic Syndrome (in addition to other known treatable causes of SFN)  but No Clear Distinction Related to Biopsy Results [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/small-fibre-neuropathy-biopsies-sfn-in-primary-fibromyalgia-revealed-predominant-association-with-metabolic-syndrome-in-addition-to-other-known-treatable-causes-of-sfn/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/small-fibre-neuropathy-biopsies-sfn-in-primary-fibromyalgia-revealed-predominant-association-with-metabolic-syndrome-in-addition-to-other-known-treatable-causes-of-sfn/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology